TEVA PHARMACEUTICAL IN

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

20 May 2025 17:21:57 By Nasdaq GlobeNewswire

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

20 May 2025 16:30:00 By Nasdaq GlobeNewswire

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

19 May 2025 04:52:49 By Nasdaq GlobeNewswire

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

19 May 2025 04:52:13 By Nasdaq GlobeNewswire

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

15 May 2025 18:12:28 By Nasdaq GlobeNewswire

Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy

12 May 2025 07:00:00 By Nasdaq GlobeNewswire

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

07 May 2025 07:00:00 By Nasdaq GlobeNewswire

Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

07 May 2025 07:00:00 By Nasdaq GlobeNewswire

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

05 May 2025 07:49:08 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

10 Apr 2025 12:37:35 By NetDania Notify

Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

07 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

07 Apr 2025 07:30:52 By Nasdaq GlobeNewswire

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

31 Mar 2025 13:00:00 By Nasdaq GlobeNewswire

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

27 Mar 2025 16:30:00 By Nasdaq GlobeNewswire

Teva Releases Q1 2025 Aide Memoire

27 Mar 2025 16:30:00 By Nasdaq GlobeNewswire

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

03 Mar 2025 16:30:00 By Nasdaq GlobeNewswire

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

27 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

25 Feb 2025 16:00:00 By Nasdaq GlobeNewswire

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

22 Feb 2025 02:20:00 By Nasdaq GlobeNewswire

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

21 Feb 2025 06:00:00 By Nasdaq GlobeNewswire